Plus, news about ADC Therapeutics, Celldex and Viracta Therapeutics:
Geron inks up to $375M royalty and debt deal: The company now
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.